BIND Therapeutics Inc (BIND)

0.14
0.01 3.33
OTC : Health Care
Prev Close 0.15
Open 0.15
Day Low/High 0.14 / 0.16
52 Wk Low/High 0.00 / 0.00
Volume 562.16K
Avg Volume 1.20M
Exchange OTC
Shares Outstanding 20.89M
Market Cap 16.29M
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
BIND Therapeutics Reports Third Quarter 2014 Financial Results And Provides Corporate Update

BIND Therapeutics Reports Third Quarter 2014 Financial Results And Provides Corporate Update

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today reported financial results and business highlights...

BIND Therapeutics Announces Agreement With Merck To Develop Targeted Accurin™ Nanomedicines For Oncology

BIND Therapeutics Announces Agreement With Merck To Develop Targeted Accurin™ Nanomedicines For Oncology

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, today announced a joint research and development agreement...

BIND Therapeutics Appoints Hagop Youssoufian, M.Sc., M.D. As Chief Medical Officer

BIND Therapeutics Appoints Hagop Youssoufian, M.Sc., M.D. As Chief Medical Officer

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, today announced the appointment of Hagop Youssoufian, M.

BIND Therapeutics Announces Availability Of Abstract With Preliminary Data From Phase 2 Study Of BIND-014 In Non-small Cell Lung Cancer

BIND Therapeutics Announces Availability Of Abstract With Preliminary Data From Phase 2 Study Of BIND-014 In Non-small Cell Lung Cancer

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced the online availability of an abstract providing...

BIND Therapeutics To Present At November Healthcare Conferences

BIND Therapeutics To Present At November Healthcare Conferences

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today that Scott Minick, BIND's President and CEO,...

BIND Therapeutics To Report Third Quarter 2014 Financial Results On November 6, 2014

BIND Therapeutics To Report Third Quarter 2014 Financial Results On November 6, 2014

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, today announced it will report third quarter 2014 financial...

Oversold Conditions For Bind Therapeutics (BIND)

Oversold Conditions For Bind Therapeutics (BIND)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

BIND Therapeutics Appoints Two New Board Members

BIND Therapeutics Appoints Two New Board Members

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, today announced the appointments of Eric K.

BIND Therapeutics To Present Data At The 26th EORTC-NCI-AACR Symposium

BIND Therapeutics To Present Data At The 26th EORTC-NCI-AACR Symposium

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today that a poster presentation including Phase 2...

BIND Therapeutics Reports Second Quarter 2014 Financial Results

BIND Therapeutics Reports Second Quarter 2014 Financial Results

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, today reported financial results for the second quarter ended...

BIND Therapeutics To Present At Wedbush 2014 Life Sciences Management Access Conference

BIND Therapeutics To Present At Wedbush 2014 Life Sciences Management Access Conference

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today that Scott Minick, BIND’s President and...

BIND Therapeutics To Report Second Quarter 2014 Financial Results On August 7, 2014

BIND Therapeutics To Report Second Quarter 2014 Financial Results On August 7, 2014

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced it will report second quarter 2014 ...

Why Bind Therapeutics (BIND) Stock Is Down in Pre-Market Trading Today

Why Bind Therapeutics (BIND) Stock Is Down in Pre-Market Trading Today

Bind Therapeutics (BIND) plunged in pre-market trading on Thursday after the company announced it had ended its partnership with Amgen (AMGN) to develop targeted cancer therapy.

Why BIND Therapeutics (BIND) Stock Is Falling In After-Hours Trading Today

Why BIND Therapeutics (BIND) Stock Is Falling In After-Hours Trading Today

BIND Therapeutics (BIND) shares are tanking after announcing that it was not pursuing a collaboration with Amgen (AMGN).

BIND Therapeutics Announces Completion Of Collaboration Agreement With Amgen

BIND Therapeutics Announces Completion Of Collaboration Agreement With Amgen

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today the completion of its collaborative research...

BIND Therapeutics And Roche Collaborate On Discovery Of Novel Nanomedicines

BIND Therapeutics And Roche Collaborate On Discovery Of Novel Nanomedicines

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, today announced that it has entered into a research agreement...

BIND Therapeutics To Present At JMP Securities Healthcare Conference

BIND Therapeutics To Present At JMP Securities Healthcare Conference

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today that Scott Minick, BIND’s President and...

Charles Rowland Elected To BIND Therapeutics Board Of Directors

Charles Rowland Elected To BIND Therapeutics Board Of Directors

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced that at BIND’s annual meeting of stockholders...

BIND Therapeutics To Present At Jefferies 2014 Global Healthcare Conference

BIND Therapeutics To Present At Jefferies 2014 Global Healthcare Conference

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today that Scott Minick, BIND’s President and...

BIND Therapeutics Reports First Quarter 2014 Financial Results And Updates BIND-014 Clinical Development Plan

BIND Therapeutics Reports First Quarter 2014 Financial Results And Updates BIND-014 Clinical Development Plan

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, today reported financial results for the first quarter ended...

BIND Therapeutics To Present At UBS Global Healthcare Conference

BIND Therapeutics To Present At UBS Global Healthcare Conference

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today that Scott Minick, BIND’s President and...

BIND Therapeutics To Report First Quarter 2014 Financial Results On May 8, 2014

BIND Therapeutics To Report First Quarter 2014 Financial Results On May 8, 2014

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, today announced it will report first quarter 2014 financial...

BIND Therapeutics Presents Clinical Data Highlighting Unique Attributes Of Lead Cancer Drug Candidate, BIND-014, At AACR 2014 Annual Meeting

BIND Therapeutics Presents Clinical Data Highlighting Unique Attributes Of Lead Cancer Drug Candidate, BIND-014, At AACR 2014 Annual Meeting

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, announced today that clinical data on its lead drug ...

Bind Therapeutics Enters Oversold Territory (BIND)

Bind Therapeutics Enters Oversold Territory (BIND)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

BIND Therapeutics Reports Fourth Quarter And Full Year 2013 Financial Results

BIND Therapeutics Reports Fourth Quarter And Full Year 2013 Financial Results

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, today reported financial results for the fourth quarter and...

BIND Therapeutics To Ring The NASDAQ Stock Market Opening Bell On March 26, 2014

BIND Therapeutics To Ring The NASDAQ Stock Market Opening Bell On March 26, 2014

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, today announced that Company management will ring the Opening...

BIND Therapeutics To Report Fourth Quarter And Year End 2013 Financial Results And Business Developments On March 25, 2014

BIND Therapeutics To Report Fourth Quarter And Year End 2013 Financial Results And Business Developments On March 25, 2014

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, today announced it will report fourth quarter and year ended...

BIND Therapeutics To Present Data At The AACR 2014 Annual Meeting

BIND Therapeutics To Present Data At The AACR 2014 Annual Meeting

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today that three poster presentations including...

BIND Therapeutics Promotes Key Executives: Organization Positioned For Continued Growth

BIND Therapeutics Promotes Key Executives: Organization Positioned For Continued Growth

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, today announced that it has structured its management team...

BIND Therapeutics To Present At 26th Annual Roth Conference

BIND Therapeutics To Present At 26th Annual Roth Conference

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today that Scott Minick, BIND’s President and...